Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Abiomed announced the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps.

News | Cardiogenic Shock

Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

October 21, 2022 — Abiomed announced the U.S. Food and Drug Administration (FDA) has accepted and closed the post ...

October 21, 2022

People with cardiovascular disease still have a high burden of risk factors for severe COVID

News | Coronavirus (COVID-19)

Smoking, Diabetes and Obesity - Not Preexisting Heart Disease - Bigger Risk of COVID-19 Death, Study Finds

October 17, 2022 — A national study suggests that risk factors for cardiovascular disease, such as age, smoking and ...

October 17, 2022

Significant findings from the highly-anticipated EPIC-STEMI study were presented during a late-breaking scientific session at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2022 Annual Symposium in Boston, MA.

Feature | TCT | Christine Book

Dramatic Cholesterol Reduction from PCSK9 Inhibitor Achieved in EPIC-STEMI Trial

October 17, 2022 — Significant findings from the highly-anticipated EPIC-STEMI study were presented during a late ...

October 17, 2022

The HELIOSTAR Balloon Ablation Catheter's unique one-shot balloon technology enables pulmonary vein isolation in 12 seconds, with customized energy delivery and one integrated 3D mapping solution

News | EP Lab

Biosense Webster Launches HELIOSTAR in Europe, the First Radiofrequency Balloon Ablation Catheter, Enabling Physicians to Perform More Efficient Cardiac Ablations

October 14, 2022 — Biosense Webster, Inc., part of Johnson & Johnson MedTech†, today announced the European launch of ...

October 14, 2022

Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP testinG, of Heart Failure therapies) study, announced the premature termination of the trial.

News | Cardiovascular Clinical Studies

STRONG-HF Study in Patients Admitted for Acute Heart Failure (HF) Terminated Early for Superior Efficacy

October 14, 2022 — Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid ...

October 14, 2022

The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extension (OLE) of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) trial, were presented at the Heart Failure Society of America (HFSA) Scientific Sessions 2022

News | Heart Failure

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

October 13, 2022 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing, and ...

October 13, 2022

the U.S. Patent and Trademark Office has issued to the University of Iowa Research Foundation ("UIRF") U.S. Patent No. 11,414,704 titled COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE, which is exclusively licensed to the Company from UIRF

News | Heart Failure

Cardio Diagnostics Announces Issuance of U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

October 13, 2022 — Cardio Diagnostics, Inc. , a pioneering precision cardiovascular testing company, announced that the ...

October 13, 2022

Zach Williams wanted to be a cancer researcher, but quick success in another area refocused his research on cardiovascular science. He was awarded a National Institutes of Health grant to fund his research for two years. Image courtesy of Clayton Metz/Virginia Tech.

News | Heart Failure

Virginia Tech Graduate Student Earns NIH Support to Explore Promising Heart Finding

October 13, 2022 — Zach Williams thought he’d become a cancer researcher when he joined Virginia Tech’s Translational ...

October 13, 2022

Videos | TCT

VIDEO: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

At TCT 2022, Deepak Bhatt, MD, MPh, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's ...

October 13, 2022

The Delphi study results show Philips’ integrated echocardiography solution provides the tools required for baseline risk stratification and monitoring of cardio-oncology patients as recommended by the latest European Society of Cardiology (ESC) guidelines

News | Heart Failure

Panel of Experts Highlights Clinical and Operational Benefits of Philips’ Integrated Echocardiography Solution

October 12, 2022 — Following the recent European Society of Cardiology (ESC) Congress in Barcelona, Spain last month, ...

October 12, 2022

Study investigates metformin and other candidate drugs through a network medicine approach

News | Heart Failure

Cleveland Clinic Researchers Identify Diabetes Drug Metformin as Potential Atrial Fibrillation Treatment in Collaborative Research

October 12, 2022 — Cleveland Clinic researchers have identified a common diabetes medication, metformin, as a possible ...

October 12, 2022

Results now available for the first 10 patients being treated with the ELANA open heart bypass solution as part of a SAFE-CAB trial.

News | Cardiovascular Clinical Studies

ELANA Heart Bypass Solution Shows Promising Preliminary Results in First-in-Human Trials

October 11, 2022 — The preliminary results of the first-in-human (FIH) trials for the innovative ELANA Heart Bypass ...

October 11, 2022

Researchers from the University of Minnesota Medical School found that patients with certain features on magnetic resonance imaging (MRI) of the heart are at much higher risk for cardiac sarcoidosis-related adverse outcomes.

News | Cardiac Imaging

Identifying Patients with Sarcoidosis at Risk for Bad Cardiac Outcomes

October 11, 2022 — Researchers from the University of Minnesota Medical School found that patients with certain features ...

October 11, 2022

Grant Proceeds Will Support Pre-Clinical Studies

News | Stents Bioresorbable

Efemoral Medical Awarded Phase II SBIR Grant from NIH to Advance Treatment for Peripheral Artery Disease

October 11, 2022 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced that it ...

October 11, 2022

News | Stroke

Identifying How Inflammation Affects Stroke Recovery

October 7, 2022 — A new research grant will enable University of Cincinnati researchers to learn more about how ...

October 07, 2022